RIGL vs. RGLS, MACK, GTHX, EBS, BOLT, XOMA, VNDA, VSTM, LXRX, and GOSS
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Regulus Therapeutics (RGLS), Merrimack Pharmaceuticals (MACK), G1 Therapeutics (GTHX), Emergent BioSolutions (EBS), Bolt Biotherapeutics (BOLT), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
Rigel Pharmaceuticals has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Regulus Therapeutics has a net margin of 0.00% compared to Rigel Pharmaceuticals' net margin of -16.45%. Rigel Pharmaceuticals' return on equity of 0.00% beat Regulus Therapeutics' return on equity.
Rigel Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Rigel Pharmaceuticals currently has a consensus target price of $5.81, suggesting a potential upside of 511.58%. Regulus Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 262.50%. Given Rigel Pharmaceuticals' higher possible upside, research analysts plainly believe Rigel Pharmaceuticals is more favorable than Regulus Therapeutics.
Regulus Therapeutics received 30 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Regulus Therapeutics. MarketBeat recorded 7 mentions for Rigel Pharmaceuticals and 4 mentions for Regulus Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.51 beat Regulus Therapeutics' score of 0.41 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.
Summary
Rigel Pharmaceuticals beats Regulus Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
